A. Rachel Leheny - Jan 23, 2024 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
CHIEF EXECUTIVE OFFICER, Director, 10%+ Owner
Signature
/s/ John Dunn, Attorney-in-Fact
Stock symbol
CALC
Transactions as of
Jan 23, 2024
Transactions value $
$400,004
Form type
4
Date filed
1/25/2024, 08:00 PM
Previous filing
Nov 8, 2023
Next filing
Apr 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Award $389K +91.1K +483.47% $4.27 110K Jan 23, 2024 Direct F1
holding CALC Common Stock 1K Jan 23, 2024 By Spouse
holding CALC Common Stock 357K Jan 23, 2024 By Valence Investments SPV IV, LLC F2
holding CALC Common Stock 66.2K Jan 23, 2024 By Valence Investments SPV V, LLC F2
holding CALC Common Stock 316K Jan 23, 2024 By Valence Investments SPV VI, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Warrant Award $5.69K +45.5K $0.13* 45.5K Jan 23, 2024 Common Stock 45.5K $5.36 Direct F1, F3
transaction CALC Warrant Award $5.69K +45.5K $0.13* 45.5K Jan 23, 2024 Common Stock 45.5K $7.15 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2 The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.
F3 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F4 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.